BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Endomatrix, Inc Opens European Subsidiary; Endomatrix Europe SL To Import And Distribute The Company's Breakthrough Cardiovascular Health Supplement, Provasca, Throughout Europe


10/19/2005 5:10:21 PM

ANTA ROSA, Calif.--(BUSINESS WIRE)--March 9, 2004--Endomatrix Inc., developer of a patented Endothelial Maintenance Program (EMP) that targets endothelial dysfunction and inflammation as the root causes of cardiovascular disease, announced today the formation of a European subsidiary, Endomatrix Europe SL. Headquartered in Barcelona, Spain, Endomatrix Europe SL will lead the company's efforts to market its dietary supplement, Provasca, in pharmacies throughout Europe.

"Years of research have gone into developing Provasca, and now we are building the business infrastructure that will allow us to share the benefits of that research with the world," said Glenn Foley, CEO of Endomatrix Inc. "Provasca's ability to maintain proper endothelial function has become increasingly important as scientists learn more about the role inflammation in cardiovascular disease, and we're extremely pleased that we can make Provasca available to individuals in Europe as well as the United States and Asia."

Endomatrix Europe SL has already received registration from the Spanish Ministry of Health as an official importer of food supplements, and hopes to expand that status to other European countries throughout the coming year. In addition, the Spanish Office of Food Security has approved Provasca for sale as a food supplement, allowing the company to begin selling the product in Spanish pharmacies immediately.

Beginning next month, Endomatrix Europe SL will employ a small sales force tasked with educating physicians about the benefits of an endothelial maintenance program that includes Provasca. The company will also work to educate pharmacists throughout the country, promoting the value of Provasca in maintaining endothelial health.

Rafael Andujar, a 26-year veteran of the European medical industry, will serve as vice president and managing director for Endomatrix Europe SL, leading the company's sales and marketing efforts. Prior to joining Endomatrix, Dr. Andujar was vice president and managing director of international functions for Precision Vascular Engineering, managed international activities for Medtronic/AVE, and spent over 20 years with C.R. Bard Inc., where he was responsible for establishing a number of international subsidiaries.

About Endomatrix

Endomatrix Inc., has developed a breakthrough platform for the treatment and prevention of endothelial-based disease states, focusing on the root cause of disease rather than the symptoms. Founded in 2000, Endomatrix is focused on delivering its platform to a global audience through both nutraceutical and pharmaceutical products. Endomatrix is based in Santa Rosa, Calif., and has subsidiaries in Barcelona, Spain, and Singapore.

About Provasca

An oral supplement designed to maintain the integrity of the vascular endothelium; Provasca introduces a patented blend of natural compounds into the arterial walls to reduce the potentially negative effects of aging, smoking and hypertension. If left unchecked, these risk factors can lead to adhesion of cholesterol and resulting inflammation of the artery walls, both of which are known causes of cardiovascular disease.

Contact:

Loomis Group for Endomatrix Inc. Dabney Oliver, 512-457-9400 oliverd@loomisgroup.com

Source: Endomatrix Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES